Skip to content
value.today

Sionna Therapeutics, Inc.

SION
$183 Mmarket cap on Oct 29, 2026
Compare
World rank
#16,585
Revenue
—
For year ending December-2025
Net income
$-75 M
SEC filing
Employees
59
As of February 15, 2026
SEC filing

Sionna Therapeutics, Inc. in brief

Sionna Therapeutics, Inc. is a listed company in the Biotechnology industry, based in Waltham, Massachusetts, USA. Its market value was $183 M on 29 October 2026, which makes it the 16,585th largest listed company in the world and the 3,209th largest in the USA on this site. It employs about 59 people and Michael Cloonan is its chief executive. Its shares trade under the symbol SION (Nasdaq).

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

About Sionna Therapeutics, Inc.

We are a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator protein to deliver clinically meaningful benefit to people with CF. CF is a progressive and life-threatening genetic disease caused by inherited mutations in the CFTR gene, which lead to insufficient CFTR function. While advances in the discovery and development of CFTR modulators have significantly improved the lives of people with CF, at least two-thirds of patients on the current standard of care do not have normal CFTR function, defined as sweat chloride levels below 30 mmol/L. Patients with reduced CFTR function can experience debilitating multi-system complications that lead to significantly impaired quality of life and shorter life expectancy. Our goal is to deliver differentiated medicines for people with CF that can restore their CFTR function to as close to normal as possible by directly stabilizing CFTR’s nucleotide binding domain 1. Despite having long been identified as a critical component for proper CFTR function, NBD1 has been considered “undruggable,” and none of the currently approved CF therapies directly stabilizes NBD1. Leveraging more than a decade of our co-founders’ research on NBD1, we are advancing a pipeline of small molecules engineered to correct the defects caused by the F508del genetic mutation, the most common CFTR mutation, which occurs in the NBD1 domain. Approximately 90% of people with CF carry at least one copy of the F508del genetic mutation.

From the company's annual report filed with the US SEC: read the report

Sionna Therapeutics, Inc. timeline

2 events, 2024–2025
  1. 2024
  2. •
    · approximate
    First filing with the US SEC
    The company's first electronic filing in SEC EDGAR.
  3. 2025
  4. 🔔
    Initial public offering on Nasdaq
    Final prospectus filed with the SEC on 7 February 2025; shares registered for exchange trading on 4 February 2025.

Events of Sionna Therapeutics, Inc. from SEC EDGAR. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

Market cap history

$0 M$79 M$158 M$237 M$315 M

World rank over time

▼ down 2,338 places since 2026
2026-08-01: #14298#14,29820262026-10-29: #16636#16,6362026

Rank in USA: #2,885 (Aug 2026) · #3,213 (Oct 2026)

Key ratios

market cap and latest results
P/E ratio
n/m (loss)
Price / sales
—
Price / book
0.6×
Free cash flow yield
-36.5%
Net margin
—
Operating margin
—
Return on equity
-24.5%
Liabilities / assets
5.9%
Profit per employee
$-1.3 M

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Dec 2024: revenue —, net income $-62M—FY24Fiscal year ending Dec 2025: revenue —, net income $-75M—FY25
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Dec 2025——$-89M$-75M—
Dec 2024——$-71M$-62M—

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Dec 2025$-66M$0M$-67M$-1.88—
Dec 2024$-53M$0M$-53M$-15.99—

Quarterly results

USD · three months to · source: SEC filings
RevenueNet income
Three months to Dec 2024 (from the annual report): revenue —, net income $-16M—Dec ’24Three months to Mar 2025: revenue —, net income $-16M—Mar ’25Three months to Jun 2025: revenue —, net income $-18M—Jun ’25Three months to Sep 2025: revenue —, net income $-20M—Sep ’25Three months to Dec 2025 (from the annual report): revenue —, net income $-20M—Dec ’25Three months to Mar 2026: revenue —, net income $-27M—Mar ’26Three months to Jun 2026: revenue —, net income $-30M—Jun ’26Three months to Sep 2026: revenue —, net income $-32M—Sep ’26

Latest quarter to Sep 2026: revenue —, net income $-32M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.

SEC filings

Official filings of Sionna Therapeutics, Inc. with the US Securities and Exchange Commission.

Annual results

Revenue
—
Operating income
$-89 M
Net income
$-75 M

For year ending December-2025 · source: SEC filing

Balance sheet

Total assets
$326 M
Total liabilities
$19 M
Total equity
$307 M

As of December-2025

Top 100 institutional investors in Sionna Therapeutics, Inc.#

As of Sep 30, 2026
136 institutions held 45.6 M shares (more than all shares outstanding: lent and sub-advised shares are reported by more than one filer) on Sep 30, 2026. The ten largest hold 72.8%. Source: SEC Form 13F filings, filed through Nov 17, 2026. Change is since the previous quarter.This quarter is still being filed: about 99% of the institutions that reported last quarter have filed so far. Institutions that have not filed yet are missing from the list, not sellers; the list is brought up to date every day.
The 25 largest institutional investors in Sionna Therapeutics, Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
1TPG GP A, LLC6,494,9620 (0.00%)14.36%$34 MNov 16, 2026
2Ra Capital Management, L.P.6,456,234-3,448,811 (-34.82%)14.27%$34 MNov 16, 2026
3Viking Global Investors LP3,195,1810 (0.00%)7.06%$17 MNov 16, 2026
4Atlas Venture Life Science Advisors, LLC2,995,6020 (0.00%)6.62%$16 MNov 10, 2026
5Goldman Sachs Group Inc2,720,289+2,331,479 (+599.64%)6.01%$14 MNov 16, 2026
6BlackRock, Inc.2,675,216+1,200,447 (+81.40%)5.91%$14 MNov 13, 2026
7Enavate Sciences GP, LLC2,478,0300 (0.00%)5.48%$13 MNov 16, 2026
8Orbimed Advisors LLC2,469,959-85,918 (-3.36%)5.46%$13 MNov 16, 2026
9Jennison Associates LLC1,992,812+820,679 (+70.02%)4.41%$10 MNov 16, 2026
10Millennium Management LLC1,462,690+1,185,957 (+428.56%)3.23%$8 MNov 16, 2026
11Aberdeen Group plc1,343,137+1,058,999 (+372.71%)2.97%$7 MNov 10, 2026
12Vanguard Capital Management LLC1,189,396+57,395 (+5.07%)2.63%$6 MNov 13, 2026
13Y-Intercept (Hong Kong) Ltd1,056,885New2.34%$6 MOct 16, 2026
14Acadian Asset Management LLC553,956New1.22%$3 MNov 9, 2026
15Geode Capital Management, LLC539,509+82,364 (+18.02%)1.19%$3 MNov 6, 2026
16Walleye Capital LLC453,319+355,972 (+365.67%)1.00%$2 MNov 13, 2026
17Marshall Wace, LLP444,016+431,417 (+3424.22%)0.98%$2 MNov 13, 2026
18Voleon Capital Management LP429,584New0.95%$2 MNov 16, 2026
19Boxer Capital Management, LLC391,723New0.87%$2 MNov 16, 2026
20Bank Of America Corp /de/378,110+289,202 (+325.28%)0.84%$2 MNov 16, 2026
21State Street Corp377,179-644,355 (-63.08%)0.83%$2 MNov 12, 2026
22AQR Capital Management LLC326,393New0.72%$2 MNov 16, 2026
23Morgan Stanley303,883+152,836 (+101.18%)0.67%$2 MNov 13, 2026
24Vanguard Portfolio Management LLC299,620+76,671 (+34.39%)0.66%$2 MNov 13, 2026
25Point72 Asset Management, L.P.263,401+214,073 (+433.98%)0.58%$1 MNov 16, 2026
Show all 100: investors 26 to 100
Institutional investors 26 to 100 in Sionna Therapeutics, Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
26BNP Paribas Financial Markets262,736+230,933 (+726.14%)0.58%$1 MNov 12, 2026
27HSBC Holdings PLC260,602New0.58%$1 MNov 16, 2026
28Trexquant Investment LP233,675+209,865 (+881.42%)0.52%$1 MNov 16, 2026
29Susquehanna Portfolio Strategies, LLC212,620+194,586 (+1079.00%)0.47%$1 MNov 16, 2026
30Schonfeld Strategic Advisors LLC170,797New0.38%$1 MNov 16, 2026
31Northern Trust Corp168,814+14,338 (+9.28%)0.37%$1 MNov 16, 2026
32Jump Financial, LLC161,330+150,857 (+1440.44%)0.36%$1 MNov 13, 2026
33Vanguard Fiduciary Trust Co148,865+27,423 (+22.58%)0.33%$1 MNov 13, 2026
34Charles Schwab Investment Management Inc146,047+16,294 (+12.56%)0.32%$1 MNov 16, 2026
35Citigroup Inc133,964+23,801 (+21.61%)0.30%$1 MNov 4, 2026
36Tang Capital Management LLC125,000New0.28%$1 MNov 16, 2026
37Quantinno Capital Management LP113,117New0.25%$1 MNov 13, 2026
38Jane Street Group, LLC105,394New0.23%$1 MNov 12, 2026
39Rock Springs Capital Management LP99,4290 (0.00%)0.22%$1 MNov 16, 2026
40Algert Global LLC91,770New0.20%$0 MNov 17, 2026
41Gsa Capital Partners LLP88,680New0.20%$0 MNov 16, 2026
42Caitong International Asset Management Co., Ltd88,580+88,549 (+285641.94%)0.20%$0 MOct 29, 2026
43Rhenman & Partners Asset Management AB87,500-9,600 (-9.89%)0.19%$0 MNov 12, 2026
44Driehaus Capital Management LLC87,272-298,175 (-77.36%)0.19%$0 MNov 16, 2026
45Ikarian Capital, LLC85,300New0.19%$0 MNov 16, 2026
46BNP PARIBAS ASSET MANAGEMENT Holding S.A.72,518New0.16%$0 MNov 13, 2026
47Axq Capital, LP71,794+67,197 (+1461.76%)0.16%$0 MNov 12, 2026
48Jain Global LLC70,918+66,138 (+1383.64%)0.16%$0 MNov 16, 2026
49Opaleye Management Inc.70,000New0.15%$0 MNov 16, 2026
50UBS Group AG65,916-50,290 (-43.28%)0.15%$0 MNov 10, 2026
51ExodusPoint Capital Management, LP65,520New0.14%$0 MNov 16, 2026
52Alps Advisors Inc59,475+13,950 (+30.64%)0.13%$0 MNov 3, 2026
53Nuveen, LLC53,199+11,940 (+28.94%)0.12%$0 MNov 10, 2026
54Dimensional Fund Advisors LP51,954New0.11%$0 MNov 4, 2026
55Bank of New York Mellon Corp46,271+4,685 (+11.27%)0.10%$0 MNov 5, 2026
56Barclays PLC46,005+39,510 (+608.31%)0.10%$0 MNov 6, 2026
57Creative Planning43,381New0.10%$0 MNov 2, 2026
58Prelude Capital Management, LLC32,361New0.07%$0 MNov 16, 2026
59Canada Pension Plan Investment Board32,100New0.07%$0 MNov 16, 2026
60UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC28,533+17,911 (+168.62%)0.06%$0 MNov 16, 2026
61Atom Investors LP27,637New0.06%$0 MNov 16, 2026
62XTX Topco Ltd27,552-10,544 (-27.68%)0.06%$0 MNov 16, 2026
63Swiss National Bank27,0000 (0.00%)0.06%$0 MNov 12, 2026
64Tower Research Capital LLC (TRC)26,094+24,815 (+1940.19%)0.06%$0 MNov 16, 2026
65Virtu Financial LLC25,448New0.06%$0 MNov 17, 2026
66Boothbay Fund Management, LLC24,860New0.06%$0 MNov 16, 2026
67Alliancebernstein L.P.24,250-1,200 (-4.72%)0.05%$0 MNov 16, 2026
68Rhumbline Advisers21,852-457 (-2.05%)0.05%$0 MNov 10, 2026
69FMR LLC21,176-257,116 (-92.39%)0.05%$0 MNov 10, 2026
70State of Alaska, Department of Revenue20,000New0.04%$0 MOct 15, 2026
71Price T Rowe Associates Inc /MD/19,585-458,431 (-95.90%)0.04%$0 MNov 16, 2026
72Jpmorgan Chase & Co18,756-1,471,752 (-98.74%)0.04%$0 MNov 12, 2026
73Wells Fargo & Company/mn16,841+20 (+0.12%)0.04%$0 MNov 16, 2026
74Deutsche Bank AG\16,734-36,619 (-68.64%)0.04%$0 MNov 6, 2026
75Citadel Advisors LLC16,188-1,131,448 (-98.59%)0.04%$0 MNov 16, 2026
76Russell Investments Group, Ltd.15,702-26,556 (-62.84%)0.03%$0 MNov 6, 2026
77Engineers Gate Manager LP15,147-456 (-2.92%)0.03%$0 MNov 16, 2026
78California State Teachers Retirement System14,8520 (0.00%)0.03%$0 MNov 13, 2026
79Two Sigma Investments, LP14,300New0.03%$0 MNov 16, 2026
80M&T Bank Corp13,781New0.03%$0 MNov 10, 2026
81Mercer Global Advisors Inc /adv13,641New0.03%$0 MNov 16, 2026
82Invesco Ltd.13,388+970 (+7.81%)0.03%$0 MNov 12, 2026
83Verdad Advisers, LP13,300New0.03%$0 MNov 16, 2026
84Simplex Trading, LLC13,194New0.03%$0 MNov 4, 2026
85Squarepoint Ops LLC13,013+7,598 (+140.31%)0.03%$0 MNov 9, 2026
86Principal Financial Group Inc11,267New0.02%$0 MNov 2, 2026
87Chicago Partners Investment Group LLC10,699New0.02%$0 MOct 27, 2026
88VANGUARD ASSET MANAGEMENT, Ltd9,5350 (0.00%)0.02%$0 MNov 13, 2026
89Legal & General Group Plc9,0440 (0.00%)0.02%$0 MNov 16, 2026
90MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.8,960-1,622 (-15.33%)0.02%$0 MNov 16, 2026
91Virtus Investment Advisers, LLC8,834-275 (-3.02%)0.02%$0 MNov 12, 2026
92China Universal Asset Management Co., Ltd.8,249+1,063 (+14.79%)0.02%$0 MOct 28, 2026
93New York State Common Retirement Fund7,700-15,886 (-67.35%)0.02%$0 MNov 17, 2026
94Nano Cap New Millennium Growth Fund L P7,500New0.02%$0 MNov 13, 2026
95GF Fund Management Co. LTD.6,667+5,721 (+604.76%)0.01%$0 MOct 26, 2026
96Vanguard Global Advisers, LLC5,831-2,021 (-25.74%)0.01%$0 MNov 13, 2026
97Police & Firemen's Retirement System of New Jersey5,4380 (0.00%)0.01%$0 MNov 9, 2026
98Strs Ohio4,900+1,400 (+40.00%)0.01%$0 MOct 30, 2026
99Arax Advisory Partners3,560+3,519 (+8582.93%)0.01%$0 MNov 12, 2026
100Vanguard Investments Australia, Ltd.3,4900 (0.00%)0.01%$0 MNov 13, 2026

All 136 institutional investors, with who bought and sold →

Superinvestors holding Sionna Therapeutics, Inc.

1 of the well-known investors value.today follows, from their newest Form 13F.

Mutual funds holding Sionna Therapeutics, Inc.#

113 funds hold shares worth $293 M. Since their previous reports 73 added shares and 23 sold, buying $7 M net.
Mutual funds holding Sionna Therapeutics, Inc.
FundSharesValueOf the companyOf the fundChange in sharesReport
🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc.934,641$41 M15.1%<0.01%+11%Jun 30, 2026
🇺🇸 State Street SPDR S&P Biotech ETFSSGA Funds Management, Inc.647,694$28 M10.5%0.27%+55%Jun 30, 2026
🇺🇸 PGIM Jennison Health Sciences FundPGIM INVESTMENTS LLC651,048$28 M10.5%2.0%no changeMay 29, 2026
🇺🇸 JPMorgan Small Cap Growth FundJ.P. Morgan Investment Management Inc.524,280$23 M8.5%0.88%−5.0%Jun 30, 2026
🇺🇸 iShares Russell 2000 ETFBlackRock Fund Advisors483,961$21 M7.8%0.03%+21%Jun 30, 2026
🇺🇸 Eventide Healthcare & Life Sciences FundEventide Asset Management, LLC474,969$21 M7.7%1.2%−26%Jun 30, 2026
🇺🇸 T. Rowe Price Health Sciences Fund, Inc.T. Rowe Price Associates, Inc.287,643$13 M4.6%0.11%−47%Jun 30, 2026
🇺🇸 Fidelity Small Cap Index FundFidelity Management & Research Company LLC201,838$10 M3.3%0.03%+26%Jul 31, 2026
🇺🇸 abrdn Healthcare Investorsabrdn Inc.201,736$9 M3.3%0.65%−49%Jun 30, 2026
🇺🇸 iShares Biotechnology ETFBlackRock Fund Advisors185,693$8 M3.0%0.09%+0.3%Jun 30, 2026
🇺🇸 iShares Russell 2000 Growth ETFBlackRock Fund Advisors173,168$8 M2.8%0.05%+31%Jun 30, 2026
🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc.168,369$7 M2.7%<0.01%+5.6%Jun 30, 2026
🇺🇸 JPMorgan Small Cap Blend FundJ.P. Morgan Investment Management Inc.166,643$7 M2.7%0.43%−6.5%Jun 30, 2026
🇺🇸 Artisan International Small-Mid FundArtisan Partners Limited Partnership116,442$5 M1.9%0.20%newJun 30, 2026
🇺🇸 Franklin Biotechnology Discovery FundFranklin Advisers, Inc.107,956$5 M1.7%0.44%+77%Jul 31, 2026
🇺🇸 abrdn Life Sciences Investorsabrdn Inc.82,402$4 M1.3%0.53%−51%Jun 30, 2026
🇺🇸 Vanguard Russell 2000 Index FundThe Vanguard Group, Inc.83,317$4 M1.3%0.02%+4.7%May 31, 2026
🇺🇸 Multi-Manager Small Cap Equity Strategies FundColumbia Funds Series Trust I83,093$4 M1.3%0.28%+1.4%May 31, 2026
🇺🇸 Select Biotechnology PortfolioFidelity Management & Research Company LLC80,900$3 M1.3%0.07%newMay 31, 2026
🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC73,777$3 M1.2%<0.01%−1.8%May 31, 2026
🇺🇸 T. Rowe Price New Horizons Fund, Inc.T. Rowe Price Associates, Inc.70,768$3 M1.1%0.02%newJun 30, 2026
🇺🇸 Schwab U.S. Small-Cap ETFCharles Schwab Investment Management, Inc.69,810$3 M1.1%0.01%+2.2%May 31, 2026
🇺🇸 Vanguard U.S. Momentum Factor ETFThe Vanguard Group, Inc.55,058$2 M0.89%0.13%+46%May 31, 2026
🇺🇸 Schwab Small-Cap Index FundCharles Schwab Investment Management, Inc.44,674$2 M0.72%0.03%+25%Jul 31, 2026
🇺🇸 Driehaus Micro Cap Growth FundDriehaus Capital Management LLC46,945$2 M0.76%0.35%newJun 30, 2026
🇺🇸 ALPS Medical Breakthroughs ETFALPS Advisors, Inc.46,379$2 M0.75%1.2%+17%May 31, 2026
🇺🇸 Master Small Cap Index SeriesBlackRock Advisors, LLC34,469$2 M0.56%0.03%+27%Jun 30, 2026
🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC27,764$1 M0.45%<0.01%no changeMay 31, 2026
🇺🇸 Nuveen Small Cap Blend Index FundTeachers Advisors, LLC24,424$1 M0.39%0.03%+26%Jul 31, 2026
🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC26,184$1 M0.42%<0.01%no changeMay 31, 2026
🇺🇸 Direxion Daily S&P Biotech Bull 3X SharesRAFFERTY ASSET MANAGEMENT, LLC22,009$1 M0.36%0.21%−7.6%Jul 31, 2026
🇺🇸 Adara Smaller Companies FundRBB Fund, Inc.22,844$1 M0.37%0.12%newMay 31, 2026
🇺🇸 iShares Core S&P Total U.S. Stock Market ETFBlackRock Fund Advisors21,536$1 M0.35%<0.01%+2.6%Jun 30, 2026
🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC21,764$1 M0.35%<0.01%+4.9%May 31, 2026
🇺🇸 EQ/2000 Managed Volatility PortfolioEquitable Investment Management Group, LLC20,147$1 M0.33%0.02%+17%Jun 30, 2026
🇺🇸 T. Rowe Price Health Sciences PortfolioT. Rowe Price Associates, Inc.17,807$1 M0.29%0.10%−50%Jun 30, 2026
🇺🇸 EQ/Small Company Index PortfolioEquitable Investment Management Group, LLC17,790$1 M0.29%0.04%+103%Jun 30, 2026
🇺🇸 Fidelity Small Cap Growth Index FundFidelity Management & Research Company LLC17,278$1 M0.28%0.05%+40%Jun 30, 2026
🇺🇸 Vanguard Balanced Index FundThe Vanguard Group, Inc.14,944$1 M0.24%<0.01%no changeJun 30, 2026
🇺🇸 Vanguard Russell 2000 Growth Index FundThe Vanguard Group, Inc.15,150$1 M0.24%0.04%+3.1%May 31, 2026
🇺🇸 LVIP Franklin Templeton Multi-Factor SMID Cap Equity FundLincoln Financial Investments Corporation14,508$1 M0.23%0.06%+76%Jun 30, 2026
🇺🇸 Vanguard Institutional Total Stock Market Index FundThe Vanguard Group, Inc.14,099$1 M0.23%<0.01%+17%Jun 30, 2026
🇺🇸 Fidelity Nasdaq Composite Index ETFFidelity Management & Research Company LLC13,843$1 M0.22%<0.01%+1.6%May 31, 2026
🇺🇸 Nuveen Equity Index FundTeachers Advisors, LLC12,533$1 M0.20%<0.01%newJul 31, 2026
🇺🇸 LVIP State Street Small-Cap Index FundLincoln Financial Investments Corporation13,200$1 M0.21%0.03%+26%Jun 30, 2026
🇺🇸 Global X Russell 2000 ETFGlobal X Management Company LLC8,820$0 M0.14%0.03%+24%Jul 31, 2026
🇺🇸 Schwab Total Stock Market Index FundCharles Schwab Investment Management, Inc.8,762$0 M0.14%<0.01%no changeJul 31, 2026
🇺🇸 Small Cap Index FundNorthern Trust Investments, Inc.9,298$0 M0.15%0.02%+30%Jun 30, 2026
🇺🇸 U.S. Small Cap Equity FundRussell Investment Management, LLC8,456$0 M0.14%0.04%no changeJul 31, 2026
🇺🇸 Fidelity ZERO Total Market Index FundFidelity Management & Research Company LLC7,675$0 M0.12%<0.01%+4.2%Jul 31, 2026
🇺🇸 Destinations Small-Mid Cap Equity FundBrinker Capital Investments, LLC8,167$0 M0.13%0.05%+1831%May 31, 2026
🇺🇸 Schwab U.S. Broad Market ETFCharles Schwab Investment Management, Inc.7,386$0 M0.12%<0.01%no changeMay 31, 2026
🇺🇸 Fidelity MSCI Health Care Index ETFFidelity Management & Research Company LLC6,417$0 M0.10%<0.01%newJul 31, 2026
🇺🇸 Blackstone Alternative Multi-Strategy FundBlackstone Alternative Investment Advisors LLC6,575$0 M0.11%<0.01%+49%Jun 30, 2026
🇺🇸 Biotechnology Ultrasector ProfundProFund Advisors LLC7,374$0 M0.12%0.16%—Apr 30, 2026
🇺🇸 Small Cap Index FundThe Variable Annuity Life Insurance Company6,453$0 M0.10%0.02%no changeMay 31, 2026
🇺🇸 Health Sciences TrustJohn Hancock Variable Trust Advisers LLC6,272$0 M0.10%0.11%−55%Jun 30, 2026
🇺🇸 MetLife Russell 2000 Index PortfolioBrighthouse Investment Advisers, LLC6,220$0 M0.10%0.03%+28%Jun 30, 2026
🇺🇸 State Street Small/mid Cap Equity Index PortfolioSSGA Funds Management, Inc.6,100$0 M0.10%<0.01%+7.0%Jun 30, 2026
🇺🇸 Fidelity ZERO Extended Market Index FundFidelity Management & Research Company LLC5,454$0 M0.09%<0.01%+9.7%Jul 31, 2026
🇺🇸 JPMorgan BetaBuilders U.S. Small Cap Equity ETFJ.P. Morgan Investment Management Inc.5,243$0 M0.08%0.04%+14%Jul 31, 2026
🇺🇸 ATM Small Cap Managed Volatility PortfolioEquitable Investment Management Group, LLC5,429$0 M0.09%0.02%+15%Jun 30, 2026
🇺🇸 Tax-Managed U.S. Mid & Small Cap FundRussell Investment Management, LLC5,014$0 M0.08%0.01%−65%Jul 31, 2026
🇺🇸 Small-Cap Index PortfolioPacific Life Fund Advisors LLC5,321$0 M0.09%0.03%+28%Jun 30, 2026
🇺🇸 EQ/AB Small Cap Growth PortfolioEquitable Investment Management Group, LLC5,150$0 M0.08%0.01%no changeJun 30, 2026
🇺🇸 Goldman Sachs ActiveBeta U.S. Small Cap Equity ETFGoldman Sachs Asset Management, L.P.5,028$0 M0.08%0.02%newMay 31, 2026
🇺🇸 EQ/T.Rowe Price Health Sciences PortfolioEquitable Investment Management Group, LLC4,455$0 M0.07%0.11%−53%Jun 30, 2026
🇺🇸 T. Rowe Price Extended Equity Market Index FundT. Rowe Price Associates, Inc.4,438$0 M0.07%0.02%no changeJun 30, 2026
🇺🇸 iShares Russell 3000 ETFBlackRock Fund Advisors4,261$0 M0.07%<0.01%−0.8%Jun 30, 2026
🇺🇸 Small Cap Core FundNorthern Trust Investments, Inc.4,219$0 M0.07%0.05%newJun 30, 2026
🇺🇸 NVIT Small Cap Index FundNATIONWIDE FUND ADVISORS4,121$0 M0.07%0.03%+30%Jun 30, 2026
🇺🇸 Small Cap Index TrustJohn Hancock Variable Trust Advisers LLC3,798$0 M0.06%0.02%+28%Jun 30, 2026
🇺🇸 Victory Extended Market Index FundVictory Capital Management Inc.3,046$0 M0.05%0.02%+6.2%Jul 31, 2026
🇺🇸 Bridge Builder Small/Mid Cap Growth FundOLIVE STREET INVESTMENT ADVISERS LLC3,064$0 M0.05%<0.01%no changeJun 30, 2026
🇺🇸 Goldman Sachs Absolute Return Tracker FundGoldman Sachs Asset Management, L.P.2,988$0 M0.05%<0.01%+3731%Jun 30, 2026
🇺🇸 iShares Russell Small/Mid-Cap Index FundBlackRock Advisors, LLC2,774$0 M0.04%<0.01%+3.2%Jul 31, 2026
🇺🇸 Siit Extended Market Index FundSEI INVESTMENTS MANAGEMENT CORPORATION3,000$0 M0.05%<0.01%no changeMay 31, 2026
🇺🇸 DWS Small Cap Index VIPDWS Investment Management Americas, Inc.2,896$0 M0.05%0.03%+27%Jun 30, 2026
🇺🇸 EQ/Morgan Stanley Small Cap Growth PortfolioEquitable Investment Management Group, LLC2,791$0 M0.05%0.03%+28%Jun 30, 2026
🇺🇸 T. Rowe Price Small-Cap Index FundT. Rowe Price Associates, Inc.2,781$0 M0.04%0.03%+52%Jun 30, 2026
🇺🇸 BlackRock Small Cap Index V.I. FundBlackRock Advisors, LLC2,502$0 M0.04%0.03%+26%Jun 30, 2026
🇺🇸 Fidelity Flex Small Cap Index FundFidelity Management & Research Company LLC2,238$0 M0.04%0.02%+3.8%Jul 31, 2026
🇺🇸 U.S. Small Cap Equity FundRussell Investment Management, LLC2,348$0 M0.04%0.04%no changeJun 30, 2026
🇺🇸 Voya RussellTM Small Cap Index PortfolioVoya Investments, LLC2,240$0 M0.04%0.02%+31%Jun 30, 2026
🇺🇸 SA Small Cap Index PortfolioSunAmerica Asset Management, LLC1,984$0 M0.03%0.03%+8.8%Jul 31, 2026
🇺🇸 Nationwide Small Cap Index FundNATIONWIDE FUND ADVISORS1,637$0 M0.03%0.03%+27%Jul 31, 2026
🇺🇸 SmallCap Growth Fund IPrincipal Global Investors, LLC1,619$0 M0.03%<0.01%+65%Jul 31, 2026
🇺🇸 PD Small-Cap Growth Index PortfolioPacific Life Fund Advisors LLC1,682$0 M0.03%0.05%+39%Jun 30, 2026
🇺🇸 CVT Russell 2000 Small Cap Index PortfolioCalvert Research and Management1,673$0 M0.03%0.02%+28%Jun 30, 2026
🇺🇸 Venerable Small Cap Index FundVenerable Investment Advisers, LLC1,468$0 M0.02%0.02%+44%Jun 30, 2026
🇺🇸 Siit Small Cap II FundSEI INVESTMENTS MANAGEMENT CORPORATION1,488$0 M0.02%0.03%no changeMay 31, 2026
🇺🇸 Vanguard Russell 3000 Index FundThe Vanguard Group, Inc.1,360$0 M0.02%<0.01%no changeMay 31, 2026
🇺🇸 Voya VACS Index Series SC PortfolioVoya Investments, LLC1,252$0 M0.02%0.03%+19%Jun 30, 2026
🇺🇸 Siit Small Cap FundSEI INVESTMENTS MANAGEMENT CORPORATION1,250$0 M0.02%0.03%−16%May 31, 2026
🇺🇸 SIMT Small Cap FundSEI Institutional Managed Trust1,210$0 M0.02%0.01%no changeJun 30, 2026
🇺🇸 Multimanager Aggressive Equity PortfolioEquitable Investment Management Group, LLC1,200$0 M0.02%<0.01%no changeJun 30, 2026
🇺🇸 VIP Extended Market Index PortfolioFidelity Management & Research Company LLC1,174$0 M0.02%<0.01%newJun 30, 2026
🇺🇸 iShares Total U.S. Stock Market Index FundBlackRock Advisors, LLC1,048$0 M0.02%<0.01%no changeJul 31, 2026
🇺🇸 iShares Morningstar Small-Cap ETFBlackRock Fund Advisors854$0 M0.01%0.01%+67%Jul 31, 2026
🇺🇸 Strategic Equity Allocation TrustJohn Hancock Variable Trust Advisers LLC822$0 M0.01%<0.01%−28%Jun 30, 2026

Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 100 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.

Insider trading at Sionna Therapeutics, Inc.#

Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.

Bought, 12 months
$0
0 purchases, 0 insiders
Sold, 12 months
$89.9 M
58 sales, 7 insiders
Net, 12 months
-$89.9 M
open market only
Insiders on file
15
since
$51.5 M-$38.9 M$0Feb 2025: bought $51.5 M (7 trades), sold $0 (0 trades)Feb 25Jun 2025: bought $950 K (1 trades), sold $0 (0 trades)Aug 2025: bought $0 (0 trades), sold $2.9 M (9 trades)AugSep 2025: bought $0 (0 trades), sold $3.5 M (8 trades)Oct 2025: bought $0 (0 trades), sold $38.9 M (61 trades)OctNov 2025: bought $0 (0 trades), sold $11.5 M (42 trades)Dec 2025: bought $0 (0 trades), sold $2.0 M (9 trades)DecJan 2026: bought $0 (0 trades), sold $10.0 M (1 trades)Feb 2026: bought $0 (0 trades), sold $1.4 M (4 trades)FebMar 2026: bought $0 (0 trades), sold $347 K (1 trades)Apr 2026: bought $0 (0 trades), sold $25.4 M (10 trades)AprMay 2026: bought $0 (0 trades), sold $13.4 M (8 trades)Jun 2026: bought $0 (0 trades), sold $5.3 M (2 trades)JunJul 2026: bought $0 (0 trades), sold $4.3 M (3 trades)Sep 2026: bought $0 (0 trades), sold $21.8 M (2 trades)Sep
Bought (open market)Sold (open market)Hover a month for the totals
Sionna Therapeutics, Inc.: latest insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed Ra Capital Management, L.P.Director, 10% ownerSellindirect-3.42 M$6.320$21.6 M3.48 MForm 4
filed Ra Capital Management, L.P.Director, 10% ownerSellindirect-33,800$7.460$252 K3.45 MForm 4
filed Elena RidloffCFO and CBOGrant or award+47,269——85,801Form 4
filed Charlotte McKeeCMO and Head of R&DGrant or award+50,000——78,415Form 4
filed Michael CloonanPresident & CEO, DirectorGrant or award+109,025——656,368Form 4
filed Jennifer FitzpatrickCLO and Head of Program Mgmt.Grant or award+28,133——28,133Form 4
filed Jennifer FitzpatrickCLO and Head of Program Mgmt.Grant or award+28,132——56,265Form 4
filed Elena RidloffCFO and CBOGrant or award+47,268——133,069Form 4

Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals

Markets and events: Sionna Therapeutics, Inc.#

Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.

Short interest, 2026-10-30
4.2 M
9.4% of shares · 4.1 days to cover
Shares sold short, last 24 reportsAll stocks →

IPO: priced at $18.00, raising $190.6M · IPO calendar

Stock splits: 1-for-1.47 reverse split

Fails to deliver

  • : 298 shares at $4.04
  • : 2,445 shares at $4.91
  • : 271 shares at $5.26
  • : 1,703 shares at $6.02
  • : 1,765 shares at $6.88

Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables

Sionna Therapeutics, Inc. scorecard#

Passes 2 of the 8 checks that could be worked out. Fiscal year 2025; market cap of Oct 29, 2026.

  • Valuation1 of 4
    • ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
    • ✓Price to book below its peers' median0.6×Price to book 0.6× against Biotechnology's median of 2.9×.
    • –Price to sales below its peers' medianNo Price to sales on file.
    • ✗Free cash flow yield above 5%-36.5%Free cash flow is -36.5% of the market value.
    • ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
    • –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
  • Growth0 of 1
    • –Revenue grew in the newest yearRevenue of the year before is not on file.
    • –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
    • –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
    • ✗Earnings per share grew in the newest year-1.88 vs -15.99Diluted EPS -1.88 in fiscal 2025 against -15.99 the year before (report's currency).
    • –Net income higher than five years earlierNet income of five years earlier is not on file.
    • –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
  • Profitability0 of 2
    • ✗Profitable in the newest year-$75 MNet income -$75 M in fiscal 2025.
    • –Profitable in each of the last five yearsFive years of net income are not on file.
    • –Operating margin above its peers' medianNo operating margin on file.
    • ✗Return on equity above 15%-105.2%-105.2% in fiscal 2025.
    • –Return on invested capital above 10%No return on invested capital on file.
    • –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
  • Financial health1 of 1
    • ✓Short-term assets cover short-term liabilities20.6×Current ratio 20.62 at the end of fiscal 2025.
    • –Debt below equityDebt or equity is not on file (or equity is negative).
    • –Net debt below three years of EBITDANet debt to EBITDA is not on file.
    • –Operating income covers interest five timesInterest expense is not on file.
    • –Cash from operations positive in each of the last three yearsThree years of operating cash flow are not on file.
    • –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
  • Shareholder returnsnot known
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • –Share count up no more than 2% in a yearShare counts of two years are not on file.
    • –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
    • –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.

Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

Sionna Therapeutics, Inc.: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

Sionna Therapeutics, Inc.: statements by fiscal year
PeriodTrendFY 2025to Dec 31, 2025FY 2024to Dec 31, 2024
Income statement
Research and development6057
General and administrative2913
Operating expenses8971
Operating income−89−71
Interest and finance income138.2
Other non-operating income (expense)148.9
Income tax00
Net income attributable to shareholders−75−62
Earnings per share, basic-1.88-15.99
Earnings per share, diluted-1.88-15.99
Shares, weighted average (basic)403.9
Shares, weighted average (diluted)403.9
Balance sheet
Cash and cash equivalents5838
Other current assets5.53.5
Current assets241151
Property, plant and equipment2.22.5
Right-of-use (leased) assets6.97.8
Total assets326186
Current liabilities1210
Lease liabilities (non-current)7.48.7
Total liabilities1919
Retained earnings−256−181
Shareholders' equity307−164
Total liabilities and equity326186
Shares outstanding454.7
Cash-flow statement
Share-based compensation123.7
Cash from operating activities−66−53
Capital expenditure−0.4−0.0
Cash from investing activities−119−127
Cash from financing activities206179
Change in cash21−0.7
Report10-K10-K

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative

Events at Sionna Therapeutics, Inc.#

What the company reported to the SEC within four business days (Form 8-K), newest first.

No warning signs in the last three years: no bankruptcy, delisting notice, withdrawn financial statements, auditor change, cybersecurity incident, debt called early or impairment was reported.

Restructuring 1 · Directors and officers 1 · Bylaws or fiscal year changed 1 · Shareholder vote 2 · Results announced 8

Sionna Therapeutics, Inc.: events reported to the SEC
FiledWhat happenedFiling
Results announced8-K
RestructuringDirectors and officers8-K
Results announced8-K
Shareholder vote8-K
Results announced8-K
Results announced8-K
Results announced8-K
Results announced8-K
Shareholder vote8-K
Results announced8-K
Results announced8-K
Bylaws or fiscal year changed8-K

Source: SEC EDGAR, Form 8-K item numbers · as of Nov 10, 2026

Layoffs at Sionna Therapeutics, Inc.#

From US state WARN notices and SEC 8-K restructuring filings, newest first.

People, last 12 months
0
1 notices and filings
People, all years
0
2026–2026
Latest
—
2026-09-09
Sionna Therapeutics, Inc.: people laid off by year and month
YearJanFebMarAprMayJunJulAugSepOctNovDecTotal
2026···········—
Sionna Therapeutics, Inc.: latest layoffs
AnnouncedPeopleKindWhereSource
46% of workforceRestructuring planSEC 8-K“The Restructuring includes a reduction of the Company’s workforce by approximately 46%, retaining core clinical, regulatory, technical, and corporate capabilities required to advan…”Filing

Source: State WARN notices and SEC 8-K item 2.05

How Sionna Therapeutics, Inc. compares in Biotechnology

  • Market cap$183 M · higher than 43% of 726
  • Price / book0.6× · lower than 89% of 534
  • FCF yield-36.5% · higher than 30% of 449

Peer comparison · Biotechnology

CompanyMarket capP/ENet marginRev. growth
Sionna Therapeutics, Inc.🇺🇸$183 M———
Novo Nordisk A/S🇩🇰$203.2 B13.1×33.1%+10.8%
Vertex Pharmaceuticals Incorporated🇺🇸$134.3 B33.8×30.7%+8.9%
Moderna, Inc.🇺🇸$90.1 B—-110.5%-39.9%
Regeneron Pharmaceuticals, Inc.🇺🇸$84.1 B17.5×28.5%+1.0%
Argenx SE🇳🇱$52.8 B40.9×31.1%+89.9%
CSL Limited🇦🇺$51.6 B—-16.4%—
Samsung Biologics Co., Ltd.🇰🇷$51.5 B40.5×39.2%—
UCB SA🇧🇪$48.6 B26.3×20.1%+31.1%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Market cap:
Oct 29, 2026
Annual results:
For year ending December-2025
Balance sheet:
As of December-2025
Employees:
As of February 15, 2026
Profile updated:
Nov 20, 2026

Figures from Market data, SEC filing, value.today research, SEC annual report; financial statements from SEC filings.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at Sionna Therapeutics, Inc.? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show Sionna Therapeutics, Inc.'s ranking on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about Sionna Therapeutics, Inc.? Suggest a correction